The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Cilostazol is able to suppress the degradation of type II collagen in human chondrocytes
induced by IL-1b. Cilostazol add-on for celecoxib therapy has synergistic anti-arthritic
potential by inhibiting proinflammatory cytokine production in synovial fibroblasts through
the IL-10/SOCS3 pathways, consequently leading to the inhibition of synovial cell
proliferation and overcoming the perpetuation of synovial inflammation.